Bone mineral density in XXXX and its relation to age at disease onset, plasmatic @entity53 and immunosuppressive therapy.

@entity1 @entity172 @entity229 @entity1252 @entity53 @entity79
OBJECTIVE: The aim of this paper was to evaluate @entity79 ( @entity79 ) in @entity1 with @entity1252 ( @entity1252 ), to determine the role of corticosteroids and cytotoxic drugs and to assess @entity172 effect on @entity79 in @entity1252 . @entity1 AND METHODS: @entity79 (DEXA) at lumbar vertebrae (L2-L4) and at femoral neck was performed in 60 pre-menopausal @entity1252 @entity1 and in 64 controls. @entity53 level was measured in all the individuals. Age, age at disease onset, body mass index (BMI), time of disease, disease activity (SLEDAI), @entity229 dose at the evaluation, total cumulative and cumulative @entity229 dose in the last year and cytotoxic drugs were assessed. RESULTS: The mean plasmatic @entity53 was 175.9 pg/ml in @entity1 and 149.9 in controls. @entity79 was inferior in @entity1 than that in controls (P < 0.0001). The mean current, cumulative and previous year @entity229 doses were, respectively, 19.17 mg/d, 28.78 g and 5.33 g. There was no association between corticosteroids or cytotoxic drug used and low bone mass. The serum concentration of @entity53 did not influence the bone mass. The BMI and age at disease onset exhibited an influence on @entity79 at L2. CONCLUSIONS: @entity79 was significantly lower in @entity1252 @entity1 but not related to CS (Corticosteroids)or other drugs; the @entity53 in these @entity1 had no effect on @entity79 . Low BMI interacting with early onset of disease might influence the probability of loss of bone mass.
